1. [Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia].
- Author
-
Belleville I, Chague F, Petit JM, and Boujon B
- Subjects
- Cabergoline, Diagnosis, Differential, Female, Heart Valve Diseases diagnosis, Humans, Middle Aged, Receptor, Serotonin, 5-HT2B drug effects, Receptor, Serotonin, 5-HT2B physiology, Aortic Valve Insufficiency drug therapy, Dopamine Agents therapeutic use, Ergolines therapeutic use, Hyperprolactinemia drug therapy
- Abstract
Used in its neurological indication, cabergoline is known to induce cardiac valve regurgitations, essentially mitral and aortic valvular diseases, by its action on the 5HT2b receptors. Until now, it was assumed that the dose and the duration of exposure were the major factors of appearance. We describe a case of aortic insufficiency which developed in a patient given low doses of cabergoline (0.5 mg weekly) for non-tumoral hyperprolactinemia. Because of previous use of appetite suppressants and of bromocriptine, the exclusive responsibility of cabergoline remained uncertain. The potential gravity of these valvular heart diseases emphasizes the importance of careful cardiologic examination before and during treatment.
- Published
- 2007
- Full Text
- View/download PDF